Trial of IMO-3100 in Patients With Moderate to Severe Plaque Psoriasis
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate different dose levels of IMO-3100 compared to
placebo administered for 4 weeks to patients with moderate to severe plaque psoriasis.